Decrease (-) Restore Default Increase (+)

Louis Ragolia, Ph.D.

Director, Biomedical Research; Associate Professor

Research

Our research focus centers around cardiovascular complications associated with obesity and type 2 diabetes.

ragolia-photo-1.jpgThe prevalence of obesity and type 2 diabetes is well-documented and continues to rise in both the United States and worldwide. Bariatric surgery has been shown to be more effective than nonsurgical treatments for sustained weight loss in moderate to severely obese type 2 diabetics. In addition to weight loss, remission of type 2 diabetes is observed in the majority of patients after the two most commonly performed bariatric operations, the Roux-en-Y gastric bypass and the sleeve gastrectomy. ragolia-photo-2.jpgThis phenomenon is even more remarkable as it occurs within days after surgery, independent of any significant weight loss. While several possible explanations have been proposed, including caloric restriction, malabsorption, and enhanced incretin secretion, the precise mechanism of how bariatric surgery ameliorates diabetes and the long-term effects on the cardiovascular system, is poorly understood.

ragolia-photo-3.jpgRecently, we reported accelerated glucose intolerance and atherosclerosis in a genetic knockout (KO) of lipocalin-type prostaglandin D2 synthase (L-PGDS). A growing body of evidence demonstrates a strong association between serum L-PGDS levels and diabetes, hypertension, and cardiovascular disease. We have exciting new data demonstrating that bariatric surgery stimulates L-PGDS expression and bile acid ragolia-photo-4.jpgsynthesis. Furthermore, we have shown that bariatric surgery is ineffective in reversing diabetes in L-PGDS KO mice. We are expanding on these findings and exploring the precise role of this protein in and bile acid metabolism in the reversal of diabetes-associated cardiovascular complications after bariatric surgery.

Since 2000, our laboratory has been funded by the American Heart Association, The American Diabetes Association, The National Institutes of Health (NHLBI), The March of Dimes, Amgen Pharmaceuticals, Reata Pharmaceuticals, The George Link Foundation, and the Theresa Santman Foundation.

Publications

  1. Kumar S, Lau R, Hall C, Palaia T, Brathwaite CE, Ragolia L. Bile acid elevation after Roux-en-Y gastric bypass is associated with cardio-protective effect in Zucker Diabetic Fatty rats. Int J Surg. 2015 Dec;24(Pt A):70-4. PubMed PMID: 26563489.
  2. Lau RG, Kumar S, Hall CE, Palaia T, Rideout DA, Hall K, Brathwaite CE, Ragolia L. Roux-en-Y gastric bypass attenuates the progression of cardiometabolic complications in obese diabetic rats via alteration in gastrointestinal hormones. Surg Obes Relat Dis. 2015 Sep-Oct;11(5):1044-53. PubMed PMID: 25980330.
  3. Ragolia L, Hall CE, Palaia T. Lipocalin-type prostaglandin D(2) synthase stimulates glucose transport via enhanced GLUT4 translocation. Prostaglandins Other Lipid Mediat. 2008 Dec;87(1-4):34-41. PubMed PMID: 18619553.
  4. Ragolia L, Palaia T, Hall CE, Maesaka JK, Eguchi N, Urade Y. Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice. J Biol Chem. 2005 Aug 19;280(33):29946-55. PubMed PMID: 15970590.